The effect of bradykinin on coronary flow and its potentiation by SH-containing ACE-inhibitors.
Bradykinin plays a role in the regulation of coronary blood flow. Under basic conditions the vasodilating effect is primarily mediated by stimulation of the endogenous nitrovasodilator endothelium-derived relaxing factor (EDRF). This effect is shortlasting but can be increased and prolonged by sulfhydryl(SH)-containing agents. ACE-inhibitors may cause coronary vasorelaxation by a bradykinin-mediated release of EDRF. This can be potentiated by the presence of SH-groups, as was shown with captopril and zofenoprilat. As a consequence, SH-containing ACE-inhibitors may potentiate nitrates, because they act as exogenous nitrovasodilators, and reverse tolerance to their therapeutic effect.
de Graeff
P A
PA
Department of Pharmacology/Clinical Pharmacology, University of Groningen, The Netherlands.
van Gilst
W H
WH
D000806:Angiotensin-Converting Enzyme Inhibitors / Q000494:pharmacology* / Q000627:therapeutic use; D000818:Animals; D001920:Bradykinin / Q000494:pharmacology* / Q000502:physiology; D003326:Coronary Circulation / Q000187:drug effects* / Q000502:physiology; D003331:Coronary Vessels / Q000187:drug effects* / Q000502:physiology; D006801:Humans; D009569:Nitric Oxide / Q000494:pharmacology; D013438:Sulfhydryl Compounds / Q000494:pharmacology; D014664:Vasodilation / Q000187:drug effects
D000806:Angiotensin-Converting Enzyme Inhibitors; D013438:Sulfhydryl Compounds; D009569:Nitric Oxide; D001920:Bradykinin